Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
75% reduction in incidence of meningitis B
(63 observed cases as compared with 253 expected cases; rate ratio: 0.25; 95% CI 0.19 to 0.36)
in a national immunisation programme in the United Kingdom1
Impact with Bexsero: National Immunisation Programme (NIP) in the United Kingdom
- Bexsero was introduced for all infants in the UK in September 20151
- Infants were administered the vaccine at 2, 4 and 12 months, which resulted in a 75% reduction in meningitis B incidence in all fully eligible children in England1
- No additional safety concerns in real world use of Bexsero beyond those identified in clinical trials in the UK and Canada3,4
Study design: 3-year observational study with impact measured by comparing observed incidence to that expected based on the 4-year prevaccination incidence in equivalent cohorts and using disease trends in vaccine-ineligible cohorts aged <5 years.1
When the age groups in which all children were eligible for vaccination were combined, the reduction in the incidence of meningococcal group B disease was 75% (63 observed cases as compared with 253 expected cases; incidence rate ratio, 0.25; 95% CI, 0.19 to 0.36).
277 cases of meningitis B were estimated to be prevented with Bexsero over the course of 3 years1,6
The same results were first published in the Archive of Diseases in Children, 2020. The graph has been independently created by GSK from the original data.
- The 277 cases averted during the program represented 1 case of meningitis B averted every 4 days1
The Bexsero Book of Experience
Video 5: Bexsero implementation in a National immunisation programme setting (UK)
VACCINATE WITH CONFIDENCE KNOWING THE REAL WORLD EVIDENCE BEHIND BEXSERO
Prescribing information (Great Britain and Northern Ireland)
Summary of product characteristics and patient information leaflet (Great Britain)
Summary of product characteristics and patient information leaflet (Northern Ireland)
References:
- Ladhani SN, et al. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309-317.
- Deceuninck G, et al. Impact of a mass vaccination campaign against serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine. 2019;37(31):4243-4245.
- Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisationin the UK: a prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395-403.
- De Serres G, Billard MN, Gariépy MC, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine. 2018;36(52):8039-8046.
- GlaxoSmithKline. Data on file 2017N320400_05. 2020.
- Isitt C, Cosgrove CA, Ramsay ME, Ladhani SN. Success of 4CMenB in preventing meningococcal disease: evidence from real-world experience. Arch Dis Child. 2020;105(8):784-790.
Bexsero is a registered trademark of the GlaxoSmithKline group of companies
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline 0800 221 441
November 2022 | PM-GB-BEX-WCNT-200002 (V3.0)
